Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus. SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.
| Market Cap | 1.19 Billion | Shares Outstanding | 191.361 Million | Avg 30-day Volume | 1.511 Million |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.69 |
| Price to Revenue | 0.0 | Debt to Equity | 0.3709 | EBITDA | -309.193 Million |
| Price to Book Value | 1.4601 | Operating Margin | 0.0 | Enterprise Value | 418.508 Million |
| Current Ratio | 3.599 | EPS Growth | -1.139 | Quick Ratio | 3.399 |
| 1 Yr BETA | 2.2373 | 52-week High/Low | 9.55 / 2.99 | Profit Margin | 0.0 |
| Operating Cash Flow Growth | -4.577 | Altman Z-Score | -1.9628 | Free Cash Flow to Firm | -353.743 Million |
| Earnings Report | 2023-08-03 |
Please sign in first
none
545.2 Thousand total shares from 6 transactions
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC FLAGSHIP VENTURES FUND V, L.P. |
|
59,027,804 | 2023-05-24 | 1 |
|
WILLIAMS DOUGLAS E EVP & PRESIDENT, R&D |
|
0 | 2023-04-10 | 2 |
|
2,314 | 2023-04-05 | 1 | |
|
5,760,888 | 2023-04-05 | 4 | |
|
MULLIGAN RICHARD HEAD OF SANAX |
|
0 | 2023-03-02 | 1 |
|
CASSIDY BERNARD J EVP & GENERAL COUNSEL |
|
0 | 2023-03-02 | 4 |
|
HARR STEVE PRESIDENT & CEO |
|
0 | 2023-03-02 | 1 |
|
HARDY NATHAN EVP, CHIEF FINANCIAL OFFICER |
|
0 | 2023-03-02 | 1 |
|
HORDO CHRISTIAN EVP, CHIEF BUSINESS OFFICER |
|
0 | 2023-03-02 | 1 |
|
44,056,353 | 2023-01-05 | 3 | |
|
MACDONALD JAMES J. EVP & GENERAL COUNSEL |
|
682,162 | 2022-06-13 | 1 |
|
239,250 | 2022-06-06 | 0 | |
|
65,000 | 2022-06-06 | 0 | |
|
65,000 | 2022-06-06 | 0 | |
|
65,000 | 2022-06-06 | 0 | |
|
65,000 | 2022-06-06 | 0 | |
|
AGARWAL SUNIL EVP, HEAD OF DEVELOPMENT & CMO |
|
1,800,000 | 2022-03-03 | 0 |
|
44,042,500 | 2021-02-08 | 0 | |
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC FLAGSHIP V VENTURELABS RX FUND, L.P. FLAGSHIP VENTURES FUND V, L.P. FLAGSHIP PIONEERING FUND VI GENERAL PARTNER LLC FLAGSHIP PIONEERING FUND VI, L.P. |
|
34,239,018 | 2021-02-08 | 0 |
|
ARCH VENTURE FUND IX OVERAGE, L.P. ARCH VENTURE FUND X OVERAGE, L.P. ARCH VENTURE PARTNERS IX, L.P. ARCH VENTURE PARTNERS IX OVERAGE, L.P. |
|
44,042,500 | 2021-02-08 | 0 |
|
1,830,610 | 2021-02-08 | 0 | |
|
ARCH VENTURE FUND IX OVERAGE, L.P. ARCH VENTURE FUND X OVERAGE, L.P. ARCH VENTURE PARTNERS IX OVERAGE, L.P. |
|
292,500 | 2021-02-03 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC - > 10% Owner by flagship v venturelabs rx fund, l.p. FLAGSHIP VENTURES FUND V, L.P. - > 10% Owner by flagship v venturelabs rx fund, l.p. FLAGSHIP V VENTURELABS RX FUND, L.P. - > 10% Owner by flagship v venturelabs rx fund, l.p. AFEYAN NOUBAR - > 10% Owner by flagship v venturelabs rx fund, l.p. |
2023-05-26 20:00:11 -0400 | 2023-05-26 | S | 9,330 | $6.23 | d | 1,425,334 | indirect | 3.7931 | 3.7931 | 2 | 0.0 | 1 | |||
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC - > 10% Owner by flagship ventures fund v, l.p. FLAGSHIP VENTURES FUND V, L.P. - > 10% Owner by flagship ventures fund v, l.p. FLAGSHIP V VENTURELABS RX FUND, L.P. - > 10% Owner by flagship ventures fund v, l.p. AFEYAN NOUBAR - > 10% Owner by flagship ventures fund v, l.p. |
2023-05-26 20:00:11 -0400 | 2023-05-26 | S | 72,670 | $6.23 | d | 11,101,994 | indirect | 3.7931 | 3.7931 | 2 | 0.0 | 1 | |||
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC - > 10% Owner by flagship v venturelabs rx fund, l.p. FLAGSHIP VENTURES FUND V, L.P. - > 10% Owner by flagship v venturelabs rx fund, l.p. FLAGSHIP V VENTURELABS RX FUND, L.P. - > 10% Owner by flagship v venturelabs rx fund, l.p. AFEYAN NOUBAR - > 10% Owner by flagship v venturelabs rx fund, l.p. |
2023-05-26 20:00:11 -0400 | 2023-05-25 | S | 13,127 | $6.35 | d | 1,434,664 | indirect | 3.7931 | 3.7931 | 2 | 0.0 | 1 | |||
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC - > 10% Owner by flagship ventures fund v, l.p. FLAGSHIP VENTURES FUND V, L.P. - > 10% Owner by flagship ventures fund v, l.p. FLAGSHIP V VENTURELABS RX FUND, L.P. - > 10% Owner by flagship ventures fund v, l.p. AFEYAN NOUBAR - > 10% Owner by flagship ventures fund v, l.p. |
2023-05-26 20:00:11 -0400 | 2023-05-25 | S | 102,245 | $6.35 | d | 11,174,664 | indirect | 3.7931 | 3.7931 | 2 | 0.0 | 1 | |||
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC - > 10% Owner by flagship v venturelabs rx fund, l.p. FLAGSHIP VENTURES FUND V, L.P. - > 10% Owner by flagship v venturelabs rx fund, l.p. FLAGSHIP V VENTURELABS RX FUND, L.P. - > 10% Owner by flagship v venturelabs rx fund, l.p. AFEYAN NOUBAR - > 10% Owner by flagship v venturelabs rx fund, l.p. |
2023-05-26 20:00:11 -0400 | 2023-05-24 | S | 39,580 | $6.57 | d | 1,447,791 | indirect | 3.7931 | 3.7931 | 2 | 0.0 | 1 | |||
|
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC - > 10% Owner by flagship ventures fund v, l.p. FLAGSHIP VENTURES FUND V, L.P. - > 10% Owner by flagship ventures fund v, l.p. FLAGSHIP V VENTURELABS RX FUND, L.P. - > 10% Owner by flagship ventures fund v, l.p. AFEYAN NOUBAR - > 10% Owner by flagship ventures fund v, l.p. |
2023-05-26 20:00:11 -0400 | 2023-05-24 | S | 308,290 | $6.57 | d | 11,276,909 | indirect | 3.7931 | 3.7931 | 2 | 0.0 | 1 | |||
| 2023-04-11 16:26:28 -0400 | 2023-04-10 | A | 1,100,000 | a | 1,100,000 | direct |
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 22:15:03 UTC | 3.3979 | 1.6721 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 21:45:05 UTC | 3.3979 | 1.6721 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 21:15:04 UTC | 3.3979 | 1.6721 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 20:45:04 UTC | 3.3979 | 1.6721 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 20:15:04 UTC | 3.3979 | 1.6721 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 19:45:04 UTC | 3.3979 | 1.6721 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 19:15:03 UTC | 3.3979 | 1.6721 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 18:45:04 UTC | 3.3787 | 1.6913 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 18:15:04 UTC | 3.3787 | 1.6913 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 17:45:04 UTC | 3.3787 | 1.6913 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 17:15:04 UTC | 3.3787 | 1.6913 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 16:45:04 UTC | 3.1517 | 1.9083 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 16:15:03 UTC | 3.1517 | 1.9083 | 150000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 15:45:04 UTC | 3.1517 | 1.9083 | 85000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 15:15:04 UTC | 3.1517 | 1.9083 | 85000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 14:45:04 UTC | 2.8923 | 2.1677 | 100000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 14:15:03 UTC | 2.8923 | 2.1677 | 90000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 13:45:03 UTC | 2.8923 | 2.1677 | 100000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 13:15:03 UTC | 2.8923 | 2.1677 | 100000 |
| SANA BIOTECHNOLOGY INC SANA | 2023-06-06 12:45:05 UTC | 2.8923 | 2.1677 | 100000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
